Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00897026 · ClinicalTrials.gov registry record

Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344

A clinical trial, sponsored by Alliance for Clinical Trials in Oncology.

Completed
Registry status
1,195
Enrollment target

NCT00897026 is a clinical trial that has completed, run by Alliance for Clinical Trials in Oncology. The registered enrollment target is 1,195 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00897026 has completed, sponsored by Alliance for Clinical Trials in Oncology.

COMPLETED
Registry status
1,195 participants
Enrollment target

Study Summary

RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors plan the best treatment. PURPOSE: This research study is looking at tissue samples from women who underwent chemotherapy for lymph node-positive stage II or stage IIIA breast cancer.

Interventions

  • DRUG cyclophosphamide
  • OTHER immunohistochemistry staining method
  • DRUG paclitaxel
  • DRUG doxorubicin hydrochloride
  • GENETIC fluorescence in situ hybridization

Trial Details

FieldValue
Enrollment Target 1,195 participants
Start Date 2008-07
Est. Completion 2012-04-27

What the Registry Record Tells You About NCT00897026

The ClinicalTrials.gov registry entry for NCT00897026 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,195 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Alliance for Clinical Trials in Oncology, which has 446 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 5 interventions - of which cyclophosphamide is the first listed.

NCT00897026 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00897026 about?

NCT00897026 is a clinical study titled "Studying Tissue Samples From Women Who Underwent Chemotherapy for Lymph Node-Positive Stage II or Stage IIIA Breast Cancer on Clinical Trial CLB-9741 or CLB-9344". RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors plan the best treatment. PURPOSE: This research study is looking at tissue samples ...

What is the current status of trial NCT00897026?

This trial is currently completed. The enrollment target is 1,195 participants. The study started on 2008-07. Estimated completion is 2012-04-27.

What interventions are being tested in trial NCT00897026?

The interventions under investigation include: cyclophosphamide (DRUG), immunohistochemistry staining method (OTHER), paclitaxel (DRUG), doxorubicin hydrochloride (DRUG), fluorescence in situ hybridization (GENETIC).

Who is sponsoring clinical trial NCT00897026?

This trial is sponsored by Alliance for Clinical Trials in Oncology, which has 446 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.